Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Protein-losing enteropathy

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise protein-losing enteropathy as a syndrome, confirm gastrointestinal protein loss only after excluding common alternatives, and direct treatment towards its mucosal, lymphatic or cardiovascular cause.

  • Protein-losing enteropathy describes excessive loss of plasma proteins into the gastrointestinal tract; it is a mechanism requiring an underlying diagnosis, not a final disease label.
  • Before attributing hypoalbuminaemia to the gut, assess hepatic synthesis, urinary protein loss, inflammation, malnutrition, burns and dilution because these are commoner explanations.
  • Mechanisms include erosive mucosal disease, non-erosive mucosal permeability and obstructed or high-pressure intestinal lymphatic drainage; several can coexist.
  • Oedema, ascites or effusions may dominate, while diarrhoea can be absent; lymphocyte and immunoglobulin loss is particularly suggestive of intestinal lymphangiectasia.
  • Faecal alpha-1-antitrypsin testing supports gastrointestinal protein loss, but collection, stool consistency, gastric acidity and laboratory method affect interpretation and a negative result does not always exclude it.
  • Endoscopy with biopsies, small-bowel imaging and cardiovascular assessment are selected from the suspected mechanism rather than ordered as an indiscriminate panel.
  • Treat the cause and replace nutritional deficits; high-protein or modified-fat strategies need specialist dietetic supervision, especially when lymphatic disease or intestinal failure is possible.
  • Albumin infusion and diuresis may temporarily manage severe fluid consequences but do not stop enteric loss and can create intravascular depletion without close monitoring.

Key red flags

Hypotension, acute kidney injury, oliguria or severe electrolyte disturbance in an oedematous patient suggests reduced effective circulating volume and needs urgent monitored management.

Sepsis, peritonism, gastrointestinal bleeding, obstruction or severe abdominal pain requires emergency assessment for an inflammatory, ischaemic, malignant or surgical cause.

Rapidly progressive anasarca, respiratory compromise from effusions or thrombosis risk during profound protein depletion warrants inpatient multidisciplinary care.

A child or adult with congenital heart palliation and new oedema, diarrhoea or low albumin needs prompt specialist cardiac assessment because haemodynamic failure may be central.

Do not commence prolonged parenteral nutrition or repeated albumin infusions without nutrition-team and cause-specific review.

Investigation priorities

01
Serum albumin and total proteinFirst step

Confirm severity and follow the biochemical trajectory.

Management branches

CONFIRMEstablish true gastrointestinal protein loss

Persistent hypoalbuminaemia, oedema or effusions lack a sufficient hepatic, renal or nutritional explanation.

  1. Confirm the trend and review inflammation, liver synthetic function, quantified urine protein, diet, fluid state, burns and medication or infusion history.
  2. Request faecal alpha-1-antitrypsin testing through the local referral laboratory, following its sampling and paired-serum requirements exactly.
  3. Assess nutritional, immune and electrolyte consequences while documenting stool frequency, bleeding, pain, surgery, cardiac history and systemic symptoms.
  4. Treat immediate fluid, infection and nutrition threats without allowing temporary biochemical improvement after albumin to be mistaken for diagnostic proof.

Key medicines

Dietary protein and energy supportIndividualised dietitian-led intake targets adjusted for ongoing losses and tolerance.Refeeding risk, renal or hepatic disease, fat malabsorption and food restriction require specialist planning; excessive protein does not correct untreated lymphatic or mucosal disease.
Human albumin solutionReserved specialist intravenous replacement linked to clinical indication and haemodynamic review.Effect is transient while enteric loss continues; pulmonary oedema, fluid redistribution and sodium load are possible, particularly with cardiac or renal dysfunction.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • Leeds Teaching Hospitals faecal alpha-1-antitrypsinNHS laboratory use and limitations of the diagnostic marker.
  • NICE CG32 Nutrition support for adultsAssessment, refeeding safeguards and oral, enteral or parenteral support.
  • BSG Chronic diarrhoea investigation guidelineBritish specialist approach to mucosal, malabsorptive and small-bowel investigation.
  • NHS England intestinal failure service consultationCurrent specialist service context for severe intestinal failure.
  • NICE QS24 Nutrition support in adultsQuality standards for safe multidisciplinary nutrition care.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom